Sienna Appoints Inaugural COO


Sienna adds talent and capacity in inaugural COO role

  • Appointment of industry leader to emerging company
  • Growing team to drive and fast-track global activities
  • Innovative telomerase technology set for roll out in US markets
Sienna Cancer Diagnostics has appointed Matthew Hoskin as Chief Operating Officer in a move which strengthens the company’s capacity as it progresses commercialisation of its innovative technology for use in a new, simple and cost-effective urine test for bladder cancer.

With more than 15 years’ experience leading business in the biotech and healthcare sectors, including Siemens Medical, Leica Biosystems and Hospira, Matthew played a key role in driving the growth at Vision Biosystems enabling it to become one of Australia's most profitable biotech companies resulting in a trade sale for ~A$800 million.

“Matthew brings to Sienna a wealth of experience in leading and growing biotech companies in both local and international markets,” said Dr Kerry Hegarty, Sienna Cancer Diagnostic Managing Director and CEO. “The purpose of this role is to implement the Sienna product launch in the US in 2014 and map out launch strategies in Europe, Australia and Asia, precisely what Matthew has done for over a decade with major multi-national diagnostic and device companies. We are thrilled he has elected to join our growing enterprise.”

Matthew has worked extensively with companies specialising in antibodies and reagent detection systems, automated IHC / ICC stainers, tissue processors, pathology capital equipment and consumables, and oncology pharmaceuticals. With manufacturing soon to commence, Sienna is expected to make additional senior appointments in order to accelerate market uptake and grow the company

Growing team to drive and fast-track global activities

Media Release - Sienna Appoints COO Media Release - Sienna Appoints COO (251 KB)


No Very

Captcha Image

Sign up for updates